top of page

LVivo AI Toolbox™

Triage and Monitor COVID-19 Patients' heart 

How COVID-19 Impacts the Heart

Clinical protocols from the American and European Societies of Echocardiography recommend conducting focused echo exams to assess heart function in patients on the emergency COVID-19 frontlines.

The Challenge: Cardiac Ultrasound Analysis During COVID-19

Point of care ultrasound (POCUS) is helping clinicians identify and monitor COVID-19 patients' heart symptoms on the frontlines.

Clinicians need automated solutions to support decisions at COVID-19 patients' bedsides.



Ultrasound analysis at Point-of-care is still mostly done visually, in a subjective process that is both prone to error and highly dependent on the user's experience



The rising number of cardiac procedures needed is creating a load on all clinicians, while clinical guides recommend minimizing scans and contact with patients


Recent data show that 51% of hospitalized COVID-19 patients who died had heart damage 


Clinicians believe what causes heart problems identified in COVID-19 patients to be one of the pandemic's “critical unknowns"

LVivo™ AI Solutions

Key Benefits

Clinical protocols recommend performing limited cardiac ultrasound scans including Left and Right ventricles analysis to detect cardiac dysfunction in patients with suspected or confirmed COVID-19.


Our FDA Cleared and CE Marked solutions, LVivo EF™ and LVivo RV™, provide automated, quantified analysis of the Left and Right Ventricle, including key measurements about each ventricle’s size and function.

Case study: DiA on the frontlines

A 66 y/o COVID-19 patient arrived at the ED with tachycardia and an ECG showing T-wave abnormality.


LVivo EF on Vscan Extend ultrasound delivered immediate results of normal Ejection Fraction (55%) which supported the physician's conclusion that viral myocarditis as the possible cause was unlikely.

LVivo EF

Ejection Fraction is a key indicator of left ventricular cardiac dysfunction, which protocols recommend monitoring to help triage COVID-19 patients.

LVivo EF by DiA provides automated analysis of the left ventricle, from 4CH and/or 2CH views, including single and Biplane: EF, End-Systolic Volume (ESV), End-Diastolic Volume (ED) Stroke Volume and Global Longitudinal Strain.


LVivo RV

Studies show that assessing the heart’s RV size and function is a key indicator of cardiac dysfunction including pulmonary embolism and heart failure common in COVID-19 patients.

LVivo RV provides automated analysis of the right  ventricle, from 4CH modified/ focused apical view including:  Fractional Area Change (FAC), EDA, ESA, Free Wall Strain and TAPSE. 

patient careWHITE.png

Objective and reproducible analysis of cardiac function


Faster and more confident clinical decisions - conserve additional resources needed


Reduce scan time, load on medical staff and bottlenecks


Minimize patient contact and potential exposure

 to infection


Ziv Dadon, M.D

Department of Cardiology

“COVID-19 has in many ways made clinicians more open to embracing new technologies that can help them work better and smarter...AI makes an important difference and I think a solution like LVivo EF has a central place in ultrasound analysis of the left ventricle.”

“COVID-19 was a great pilot in terms of increasing awareness of how AI can assist with diagnosis. Being able to assess cardiac contractility Ejection Fraction rapidly is really important. An AI-driven tool like LVivo is going to improve the ability to rapidly triage and evaluate patients.”


Bret Nelson, M.D

Department of Emergency Medicine


“LVivo EF is a great app. I have used it a lot on ICU during COVID-19 to highlight some of the effects of the virus on the cardiac muscle.” 

Jonny Wilkinson, M.D

Intensive care and anaesthesia


"LVivo EF makes it possible for clinicians to quickly, accurately and safely analyze cardiac function at bedside. For patients with COVID-19...being able to rapidly and accurately detect the EF at the point of care can save precious time and improve patient outcomes."

Evan (Avi) Alpert, M.D

Department of Emergency Medicine

Our Partners

DiA's AI solutions run on the CPU and GPU of any ultrasound device or Healthcare IT system (PACS/ Cloud).


 COVID-19 Resources

Why are COVID-19 ARDS patients difficult to manage? Pathology has an answer.

Right Ventricular Dilation in Hospitalized COVID-19 Patients Can Be Indicator of High-Risk Cases

The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) - a Systematic Echocardiographic Study

ASE Statement on COVID-19: Guideline on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak

COVID-19 infection – Learnings from Italy

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

COVID-19 and the Heart: Insights From the Front Lines

A Heart Attack? No, It Was the Coronavirus

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel

Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury

Acute right ventricular failure in COVID-19 infection: A case series9 complications

Partner with DiA to realize our COVID-19 mission

The time for AI-powered ultrasound is now. We’re proud to be working with

our partners and clinicians across the globe to maximize the benefits of AI

in the fight against COVID-19.


If you are an ultrasound user, vendor, or PACS company, please join us to help clinicians and patients on the COVID-19 frontlines.

bottom of page